1
Takeru Higuchi: Osmotic drug delivery system. Merck & Co, Rudolph J Anderson, Mario A Monaco Jr, Michael C Sudol Jr, March 27, 1984: US04439196 (242 worldwide citation)

An osmotic drug (or other beneficial substance) delivery system comprises a multi-chamber compartment formed by an external shell and one or more chamber-dividing walls each with a small orifice, of a microporous material and overlayers of semipermeable membranes completely covering the outer shell ...


2
William F Hoffman, Robert L Smith, Alvin K Willard: Antihypercholesterolemic compounds. Merck & Co, William H Nicholson, Mario A Monaco, April 24, 1984: US04444784 (222 worldwide citation)

6(R)-[2-(8'-acyloxy-2'-methyl-6'-methyl (or hydrogen)-polyhydronaphthyl-1')-ethyl]-4 (R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones are prepared by acylation of the corresponding 8'-hydroxy compounds. The products are strong inhibitors of the biosynthesis of cholesterol.


3
Gary H Rasmusson, David B R Johnston, Glen E Arth deceased: 4-Aza-17.beta.-substituted-5.alpha.-androstan-3-one-reductase inhibitors. Merck & Co, Thomas E Arther, Mario A Monaco, March 22, 1983: US04377584 (138 worldwide citation)

4-Aza-17.beta.-substituted-5.alpha.-androstan-3-ones and their A-homo analogs of the formula: ##STR1## where Formula (I) may also have the structure of partial Formulas (II) and/or (III);


4
Raymond Joseph Schaper: Functional ionene compositions and their use. Calgon Corporation, Rudolph J Anderson Jr, Mario A Monaco, Martin L Katz, February 21, 1978: US04075136 (136 worldwide citation)

Novel functional ionene polymer compositions have been prepared which have been found to be useful in a wide variety of applications, including, among others, as wet and dry strength additives, corrosion inhibitors, and electroconductive coatings, and which comprise recurring units of the formula: # ...


5
Raymond J Schaper: Functional ionene compositions and their use. Calgon Corporation, Mario A Monaco, Martin L Katz, Raymond M Speer, September 4, 1979: US04166894 (124 worldwide citation)

Novel functional ionene polymer compositions useful in a wide variety of applications, including, among others, as wet and dry strength additives, corrosion inhibitors, and electroconductive coatings.


6
William F Hoffman, Robert L Smith, Alvin K Willard: Antihypercholesterolemic compounds. Merck & Co, William H Nicholson, Mario A Monaco, May 22, 1984: US04450171 (119 worldwide citation)

6(R)-[2-(8'-acyloxy-2'-methyl-6'-methyl (or hydrogen)-polyhydronaphthyl-1')-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H- pyran-2-ones are prepared by acylation of the corresponding 8'-hydroxy compounds. The products are strong inhibitors of the biosynthesis of cholesterol.


7
Robert E Dempski, Gunvant N Mehta, Joseph C Saboe: Sustained release indomethacin. Merck & Co, William H Nicholson, Mario A Monaco, November 6, 1979: US04173626 (103 worldwide citation)

A sustained release indomethacin pharmaceutical product is provided that utilizes a pellet formulation encapsulated in a hard gelatin capsule. A portion of the pellets is uncoated for immediate and rapid release of indomethacin for elevating the plasma level. The remainder of the pellets are coated ...


8
Richard J Harwood: Transdermal delivery of drugs. Merck & Co, Thomas E Arther, Mario A Monaco, Rudolph J Anderson Jr, October 28, 1980: US04230105 (101 worldwide citation)

An improved method for the topical administration of systemically or locally active drugs utilizes a bandage containing one or more layers including a drug useful in the treatment of disease and a heat-generating substance, each dispersed intimately throughout said bandage layers.


9
Alvin K Willard, Frederick C Novello, William F Hoffman, Edward J Cragoe Jr: Substituted pyranone inhibitors of cholesterol synthesis. Merck & Co, William H Nicholson, Mario A Monaco, March 1, 1983: US04375475 (97 worldwide citation)

6-Phenyl-, phenylalkyl- and phenylethenyl-4-hydroxytetrahydropyran-2-ones in the 4(R)-trans stereoisomeric forms are potent inhibitors of cholesterol synthesis by virtue of their ability to inhibit the enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A reductase.


10
Jacob A Zupan: Use of eucalyptol for enhancing skin permeation of bio-affecting agents. Merck & Co, Manfred Polk, Michael C Sudol Jr, Mario A Monaco, April 3, 1984: US04440777 (85 worldwide citation)

Greatly enhanced delivery of a wide variety of bio-affecting agents is provided by formulations for topical application comprising at least one bio-affecting agent and eucalyptol. Optionally, the formulation can further comprise a non-toxic topical carrier and/or an additional penetration enhancer. ...